Application of Gallic Acid Extracted from Emblica officinalis in Plant Disease Control
By extracting and isolating gallic acid from the yuganzi pomace, the side effects of chemical agents and resource waste in the prevention and treatment of potato scabs have been solved, effective development of plant-source fungicides and biological fertilizers have been achieved, and sustainable utilization of resources has been promoted. .
Patent Information
- Application Number
- CN202210288987.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-23
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-03-23
AI Technical Summary
The prior art relies on chemical agents in the prevention and treatment of potato scabs, which have side effects and environmental pollution problems, and the remaining sweet potato pomace resources have not been effectively utilized.
Gallic acid was extracted and isolated from the saccharin pomaceps and was found to have the activity of inhibiting Streptomyces potato scab and was used to prepare plant-derived fungicides and biological fertilizers.
Effectively prevent and treat potato scab disease, provide natural, low-toxic and pollution-free pesticide alternatives, and promote the resource utilization of yuganzi fruit pom, reducing environmental pollution and resource waste.
Smart Images

Figure BDA0003560963980000051 
Figure HDA0003560963990000011 
Figure HDA0003560963990000012
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of active drugs, and in particular to application of gallic acid extracted from emblica buds in preventing and treating plant diseases. Background Art
[0002] Phyllanthus emblica L. is the fruit of the genus Phyllanthus in the Euphorbiaceae family. It is primarily distributed in tropical and subtropical regions. Native to India, it is also found in Pakistan, Malaysia, and China, with the largest production in Fujian and Yunnan provinces in China. As early as 1998, it was designated by the Ministry of Health as both a food and a medicine, and has been included in multiple editions of the Pharmacopoeia of the People's Republic of China. The World Health Organization has designated it as one of three health-promoting plants for global cultivation. The unique composition and pharmacological activities of emblica make it highly valuable for development and application, and the related industry has experienced rapid growth in recent years.
[0003] Currently, the development of emblica buds primarily focuses on extraction and fresh fruit juicing, followed by processing into beverages, refined powders, and lozenges. This production process generates waste products such as pits, pomace, or medicinal residues. The extract preparation process also produces significant amounts of sediment, filtered solids, and other byproducts. Data indicates that the weight of emblica buds alone can account for approximately 65% of the original fruit weight, and pharmaceutical companies produce nearly 100 tons of emblica buds pharmaceutical solid residue annually. Discarding or landfilling these residues alone is costly, environmentally taxing, and wastes significant resources. Therefore, research into the development of emblica buds pomace not only helps prevent environmental pollution but also enables the production of high-value-added products. This fundamentally addresses the issue of pomace utilization and fosters a sustainable path for the resourceful utilization of emblica buds pomace.
[0004] Potatoes are the fourth most important food crop globally, after wheat, rice, and corn. Potatoes can be used not only as a food crop for human consumption but also as a cash crop for a variety of industries. Their high nutritional value, strong adaptability to the environment, and significant potential for yield increases suggest a promising future for potato scab. Over 20 species of pathogens have been reported to cause potato scab, the most common of which are Streptomyces scabies, S. acidiscabies, and S. turgidiscabies. S. scabies is the primary causative agent of potato scab. Symptoms include scab-like, raised, or sunken lesions on the tuber surface, which severely impact potato quality, reduce its market value, and cause significant economic losses to growers. S. scabies can also infect taproot crops such as radishes, beets, carrots, and parsnips. Soil-borne bacterial plant diseases caused by pathogenic Streptomyces species remain a significant constraint on the positive development of the potato industry in China and around the world. While chemical pesticides are currently effective, they can also produce side effects, such as smaller potato tubers, reduced yields, and threats to the environment and human health. Therefore, the search for highly effective, low-toxic botanical pesticides derived from natural plant sources presents a promising alternative, offering advantages such as a shorter cycle time, low toxicity, no pollution, and ease of production. These botanical pesticides are an effective green approach to agricultural product control. Summary of the Invention
[0005] In order to solve the above problems, the present invention proposes an application of gallic acid extracted from emblica fruit in plant disease prevention and control. Gallic acid is extracted, separated and purified from emblica fruit pomace, and is found for the first time to have the activity of inhibiting Streptomyces potato scab, and can be used to prevent and control potato scab.
[0006] In order to achieve the above object, an embodiment of the present invention provides an application of gallic acid extracted from emblica buds in the prevention and treatment of plant diseases, wherein the plant disease is potato scab.
[0007] According to the application of the embodiment of the present invention, gallic acid is extracted, separated and purified from the pomace of the fruit of the emblica, and is found for the first time to have the activity of inhibiting Streptomyces scab, and can be used to prevent and treat potato scab.
[0008] Optionally, the preparation of gallic acid comprises:
[0009] The pomace of emblica fruit was soaked in 70% ethanol and extracted by ultrasonic acceleration, and the extraction was repeated 3 times. The extracts were combined and the solvent was dried by rotary evaporation to obtain the crude ethanol extract EA.
[0010] The crude extract EA of the ethanol layer was dissolved in 50% methanol water and separated and purified using a medium-low pressure reverse phase C18 column at a flow rate of 30 mL / min and eluted with 25% methanol water. The fraction from 15 to 31 min was collected as fraction EA-1.
[0011] Component EA-1 was dissolved in methanol and separated and purified using Sephadex LH-20 at a flow rate of 0.25 mL / min, using methanol as the eluent. The fractions at 3540–4080 min were collected as component EA-1-3.
[0012] Component EA-1-3 was dissolved in methanol and purified by high-performance liquid chromatography (HPLC). The mobile phase consisted of a 1% methanol-water mixture with 0.075% trifluoroacetic acid. The flow rate was 10 mL / min, the injection volume was 100 μL, the column temperature was 25°C, and the detection wavelengths were 210 nm and 280 nm. The fractions collected between 45 and 47 min were component A-1-3-7, which was identified by nuclear magnetic resonance imaging as gallic acid. Thus, the separation was performed using the readily available raw material, which allows for full recycling of the pomace and avoids waste. The preparation process was simple and easy to operate. The resulting gallic acid was extracted, isolated, and purified from the pomace. It was found for the first time to have inhibitory activity against Streptomyces scab, and can be used as a botanical fungicide for potato scab. This provides a new source for the development of botanical pesticides and is of great significance for the research of active ingredients in natural products from traditional Chinese medicinal materials with medicinal and edible properties.
[0013] In another aspect, embodiments of the present invention further provide the use of gallic acid extracted from emblica fruit in the preparation of biofertilizer, wherein the gallic acid is used to inhibit the activity of Streptomyces scabiei. Thus, gallic acid is extracted from emblica fruit pomace, separated and purified, and is found for the first time to have an inhibitory effect on Streptomyces scabiei, thus being used as a biofertilizer.
[0014] Additional aspects and advantages of the present invention will be set forth in part in the description which follows and, in part, will be obvious from the description which follows, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is a graph showing the antibacterial experiment of the crude ethanol extract (EA) according to an embodiment of the present invention;
[0016] Figure 2 This is a graph showing the antibacterial experiment of the extract EA-1 according to an embodiment of the present invention;
[0017] Figure 3 This is a graph showing the antibacterial experiment of the extract EA-1-3 according to an embodiment of the present invention;
[0018] Figure 4This is a graph showing the antibacterial experiment of the extract EA-1-3-7 according to an embodiment of the present invention;
[0019] Figure 5 This is a diagram of a positive control antibacterial experiment according to an embodiment of the present invention;
[0020] Figure 6 This is a diagram of a solvent control antibacterial experiment according to an embodiment of the present invention;
[0021] Figure 7 HPLC analysis chart of gallic acid, a compound according to an embodiment of the present invention;
[0022] Figure 8 According to the compound gallic acid of the embodiment of the present invention 1 H-NMR spectrum;
[0023] Figure 9 According to the compound gallic acid of the embodiment of the present invention 13 C-NMR spectrum;
[0024] Figure 10 is the minimum inhibitory concentration of gallic acid at different concentrations according to the embodiments of the present invention. DETAILED DESCRIPTION
[0025] The technical solution of the present invention is described below through specific examples. It should be understood that the one or more method steps mentioned in the present invention do not exclude the presence of other method steps before and after the combination step or the insertion of other method steps between these explicitly mentioned steps; it should also be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention. Moreover, unless otherwise specified, the numbering of each method step is only a convenient tool for identifying each method step, and is not intended to limit the order of arrangement of each method step or to define the scope of the present invention. Changes or adjustments in their relative relationships, without substantially changing the technical content, should also be regarded as the scope of the present invention.
[0026] In order to better understand the above technical solutions, exemplary embodiments of the present invention are described in more detail below. Although exemplary embodiments of the present invention are shown, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided to enable a more thorough understanding of the present invention and to fully convey the scope of the present invention to those skilled in the art.
[0027] The test materials used in the present invention are all common commercial products and can be purchased in the market.
[0028] It should be noted that the Oxford cup method used in the following examples is: in a sterile operating table, the prepared Gao's No. 1 solid culture medium is placed next to the flame of an alcohol lamp, 200 μL of the scab Streptomyces spore suspension prepared in advance is drawn with a sterile pipette, carefully and evenly blown on the surface of the culture medium, and evenly lightly coated with a sterile coating rod until there is no obvious moisture on the surface and the coating rod has a pulling feeling. After the coating is completed, the sterilized Oxford cup is placed on the surface of the culture medium, and the Oxford cup is gently pressed with sterile tweezers to be trapped in the surface of the culture medium (not too deep to touch the bottom). 200 μL of sample solution is added to each Oxford cup, placed in a constant temperature incubator at 30°C and cultivated, and observed after 48h whether there is an inhibition zone. Chloramphenicol (1 mg / mL) is used as the positive control group, and methanol is the solvent control group. Three parallel groups are set for each experiment.
[0029] The present invention is described below with reference to specific examples. It should be noted that these examples are merely illustrative and do not limit the present invention in any way.
[0030] Example 1
[0031] A method for preparing gallic acid from emblica buds, comprising the following steps:
[0032] Step 1, get 740g of the fresh fruit of the emblica, after de-nucleating and juicing, obtain 234g of pomace.The emblica pomace is placed in a 5000mL beaker, soaked with 2000mL 70% ethanol and extracted with ultrasonic acceleration for 1h, repeated extraction 3 times, merged the extract, and drained the solvent with a rotary evaporator to obtain 19.74g of ethanol layer crude extract (EA).
[0033] Step 2: 19.74 g of the crude ethanol extract (EA) obtained in step 1 was dissolved in 50 mL of 50% methanol-water and eluted with 25% aqueous methanol using a medium-low pressure reverse-phase C18 column (filler: YMC-GEL ODS-A-HG, s-50 μm; column length 4.5 × 35 cm) at a flow rate of 30 mL / min. The elution was performed with 25% aqueous methanol to collect the 15-31 min fraction (EA-1).
[0034] Step 3: Dissolve 1.03 g of (EA-1) obtained in step 2 in 15 mL of 100% methanol. Use Sephadex LH-20 (2.5×170 cm) and 100% methanol as the eluent at a flow rate of 0.25 mL / min. Collect the fractions (EA-1-3) at 3540–4080 min.
[0035] Step 4. Collect 336.5 mg of (EA-1-3) obtained in step 3 and dissolve it in 5 mL of 100% methanol. Purify it using a Huideyi preparative high performance liquid chromatograph; chromatographic column: YMC-AQ, 20×250 mm, s-10 μm, mobile phase: 1% methanol-water mixture, followed by the addition of 0.075% trifluoroacetic acid; flow rate: 10 mL / min; injection volume: 100 μL; column temperature: 25°C; detection wavelengths: 210 nm and 280 nm; collect the 45-47 min components (EA-1-3-7) and concentrate to obtain approximately 26.1 mg of the compound.
[0036] The process uses the Oxford cup method, and the antibacterial activity of the crude extract and the components obtained in each step is tracked in turn, and the parts with higher antibacterial activity are selected for subsequent tests. Among them, the antibacterial test of the crude extract of the ethanol layer (EA) is as follows Figure 1 As shown in the antibacterial experiment of EA-1 Figure 2 As shown in the antibacterial experiment of EA-1-3, Figure 3 As shown in the figure, the antibacterial test of EA-1-3-7 is as follows Figure 4 As shown, the positive control 1mg / mL chloramphenicol) antibacterial experiment is as follows Figure 5 As shown, the solvent control (methanol) antibacterial experiment is as follows Figure 6 As shown, compound EA-1-3-7 was finally traced, separated and purified.
[0037] The compound EA-1-3-7 prepared in this example was a white powder and was subjected to HPLC analysis. The HPLC parameters were as follows: HPLC model: Agilent Technologies; detector: 1260 Infinity II; chromatographic column: Welch-LP-C18 column, 4.6×250 mm, s-5 μm; liquid phase conditions: mobile phase: 1% methanol-water mixture, followed by 0.1% trifluoroacetic acid, isocratic elution for 20 min; flow rate: 1 mL / min, column temperature: 35°C, injection volume: 20.0 μL; detection wavelength: 280 nm.
[0038] The results are as follows Figure 7 As shown, the high performance liquid chromatography detection chart of compound EA-1-3-7 at a detection wavelength of 280 nm has a retention time of 11.636 min.
[0039] Mass spectrometry determination of compound EA-1-3-7:
[0040] Instrument model: Q Exactive triple quadrupole tandem mass spectrometer, Thermo, Bremen, Germany;
[0041] Mass spectrometry conditions: ESI source, positive ion mode, emission current 34.6 μA; curtain gas (CUR) 20.0 psi; ion source voltage (IS) 2500 V; ion source temperature (TEM) 420°C; interface temperature 260°C; nebulizer gas (GS1) 40 psi; auxiliary gas (GS2) 40 psi; mass range 100-1000 m / z.
[0042] The molecular weight of the obtained compound EA-1-3-7 was ESI-MS (m / z): 171.1488 [M+H] + .
[0043] The compound EA-1-3-7 was subjected to nuclear magnetic resonance determination:
[0044] NMR instrument: Bruker Avance II-500 NMR spectrometer, test temperature: 296K; solvent: deuterated methanol; internal standard: tetramethylsilane (TMS); 1 H-NMR: 500 MHz; 13 C-NMR: 125 MHz.
[0045] The results are as follows Figure 8 and Figure 9 . 1 H-NMR (500 MHz, CD3OD) data are as follows: δ: 7.06 (2H, s, H-2, 6);
[0046] 13 C-NMR (125 MHz, CD3OD) data are as follows: δ: 122.1 (C-1), 110.5 (C-2, 6), 146.5 (C-3, 5), 139.7 (C-4), 170.5 (C-7).
[0047] Based on the NMR and mass spectrometry data of compound EA-1-3-7 and comparison with the literature, it is speculated that compound EA-1-3-7 is gallic acid; English name: Gallic acid; molecular formula: C7H6O5; relative molecular weight: 170; structure is as follows:
[0048]
[0049] Example 2
[0050] In a clean bench, take a strain (Streptomyces ulmoides AMCC400023) preserved on a slant medium and carefully pick a single colony with a cooled inoculating loop near the flame of an alcohol burner. Use the plate streak method to inoculate the pathogen onto Gao's solid medium No. 1, seal the edges with parafilm, and incubate in a 30°C constant-temperature biochemical incubator for 48 hours. Gao's solid medium No. 1 (g / L): potassium nitrate: 1.0; potassium dihydrogen phosphate: 0.5; magnesium sulfate: 0.5; ferrous sulfate: 0.01; sodium chloride: 0.5; soluble starch: 20.0; agar: 15.0.
[0051] Use an inoculation loop to pick up a single colony of Streptomyces scabii that has been activated, streak it tightly on Gao's No. 1 culture medium, and culture it at a constant temperature of 28°C for 3 days; draw 3 mL of sterile water on the plate, gently scrape off the surface spores with a blade, rinse the surface of the culture medium with small amounts several times, and dilute it to a concentration of 10 7 The bacterial suspension was collected into a 50 mL centrifuge tube and stored at 4 °C until use.
[0052] Take the gallic acid obtained in Example 1 above and use 50% methanol aqueous solution to prepare a liquid medicine with a concentration of 40 mg / mL. Take 0.5 mL of the liquid medicine and add it to a 2 mL centrifuge tube containing 0.5 mL of Gao's No. 1 liquid culture medium, which is tube No. 1. Take another 8 2 mL centrifuge tubes containing 0.5 mL of Gao's No. 1 liquid culture medium and add 0.5 mL of the liquid medicine drawn from the previous tube respectively, and dilute them by half in sequence. Discard 0.5 mL of the last tube (that is, draw 0.5 mL of liquid from tube No. 1 and add it to tube No. 2, mix it; draw 0.5 mL of liquid from tube No. 2 and add it to tube No. 3, and so on, for a total of 9 tubes. In order to ensure that the volume of each tube is consistent, the last tube (tube No. 9) draws 0.5 mL and discards it), tube No. 10 uses 0.5 mL of methanol aqueous solution as the solvent control, tube No. 11 uses 0.5 mL of 1 mg / mL chloramphenicol as the positive control, and these 11 tubes are finally respectively Add 0.5mL of the prepared bacterial solution to make the final concentration of the drug in each tube 20mg / mL, 10mg / mL, 5mg / mL, 2.5mg / mL, 1.25mg / mL, 0.625mg / mL, 0.3125mg / mL, 0.15625mg / mL, 0.078125mg / mL, 0mg / mL and 0mg / mL, respectively. Place the tube in a shaker at 30℃ and 150rpm for 24h, and observe the growth of the bacteria in each tube. If the bacteria in the first tube do not grow but the bacteria in the second tube do grow, the drug concentration corresponding to the first tube is the minimum inhibitory concentration of gallic acid for the bacteria. The results are as follows Figure 10 As shown, the minimum inhibitory concentration of gallic acid against Streptomyces scab was 1.25 mg / mL, and the inhibition zone of gallic acid (15 mg / mL) was 2.83 cm (the diameter of the Oxford cup was 7 mm).
[0053] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic expressions of the above terms should not be understood as necessarily referring to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification.
[0054] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.
Claims
1. The application of gallic acid in plant disease prevention and control, characterized in that: The plant disease is potato scab; the preparation of gallic acid comprises: The pomace of Phyllanthus emblica was soaked in 70% ethanol and subjected to ultrasonic accelerated extraction, and the extraction was repeated for 3 times. The extracts were combined and the solvent was drained by rotary evaporator to obtain the ethanol layer crude extract EA. The crude extract EA of the ethanol layer was dissolved in 50% methanol water, separated and purified using a medium-low pressure reverse phase C18 column, with a flow rate of 30 mL / min, eluted with 25% methanol water solution, and the 15-31 min fraction was collected as fraction EA-1; Component EA-1 was dissolved in methanol and separated and purified using Sephadex LH-20 with a flow rate of 0.25 mL / min and methanol as the eluent. The 3540-4080 min components were collected as component EA-1-3. Component EA-1-3 was dissolved in methanol and purified by high performance liquid chromatography. The mobile phase was a 1% methanol-water mixture, and 0.075% trifluoroacetic acid was added. The flow rate was 10 mL / min. The injection volume was 100 μL. The column temperature was 25 °C. The detection wavelengths were 210 nm and 280 nm. The components from 45 to 47 min were collected, which were component A-1-3-7. The components were identified as gallic acid by nuclear magnetic resonance.
Citation Information
Patent Citations
Controlling agent of hardly controllable soilborne disease by gallic acid-related material, and method for controlling hardly controllable soilborne disease by using the same
JP2009298736A
